Vida, Bayer throw weight behind $175M T-cell startup

yellow cells

Affini-T Therapeutics has formally launched with $175 million in venture capital, one clinical-stage drug licensed from Fred Hutch and two more solid tumor-targeting drugs that should enter the clinic next year.

New Cell Therapy Player Makes Public Debut at JPM

Affini-T Therapeutics, a new cell therapy company launched by researchers from Fred Hutchinson Cancer Center, made its public debut at the 2022 J.P. Morgan Healthcare Conference with a mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients. First reported by Geek Wire, Affini-T, based in Boston, is harnessing T cell […]